MELBOURNE, Australia and SAN FRANCISCO, June 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, trading under the ASX code ATHDA until 12 June; NASDAQ: ATHE) ("Alterity" or "the Company"), ...
- Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration - - FDA agrees on UMSARS Part I ...
The regulator ticks off on key elements of a phase III trial, including study population, endpoint selection, dosing regimen and treatment duration Alterity’s Multiple System Atrophy (MSA) candidate ...
An over 30-hour manhunt for a West Texas fugitive wanted for the attempted murder of a police officer ended Friday after the man fired random shots at passing cars as police closed in on him, killing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results